Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ: ENTA )

7.270 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
From Enanta Pharmaceuticals, Inc.
Via Business Wire
10 Companies That Had Tons of Money in SVB When It Collapsed
Silicon Valley Bank is gone but its clients are still here. Many prominent companies, and not just startups, had money in SVB. 
Via InvestorPlace
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals's Earnings: A Preview
Via Benzinga
Earnings Outlook For Enanta Pharmaceuticals
Via Benzinga
Recap: Enanta Pharmaceuticals Q3 Earnings
  Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q3 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in Two Investor Conferences in November
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For November 21, 2022
Companies Reporting Before The Bell • Zepp Health (NYSE:ZEPP) is expected to report quarterly earnings at $0.54 per share on revenue of $186.58 million. 
Via Benzinga
Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium
From Enanta Pharmaceuticals, Inc.
Via Business Wire
New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
From Enanta Pharmaceuticals, Inc.
Via Business Wire
What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Recap Of Friday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Enanta Shares Rise On Positive Data From Initial-Stage Covid-19 Study
Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS